226 related articles for article (PubMed ID: 7799046)
1. Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial.
Bajorin DF; Nichols CR; Schmoll HJ; Kantoff PW; Bokemeyer C; Demetri GD; Einhorn LH; Bosl GJ
J Clin Oncol; 1995 Jan; 13(1):79-86. PubMed ID: 7799046
[TBL] [Abstract][Full Text] [Related]
2. Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma.
Hamm J; Schiller JH; Cuffie C; Oken M; Fisher RI; Shepherd F; Kaiser G
J Clin Oncol; 1994 Dec; 12(12):2667-76. PubMed ID: 7989942
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group.
Le Cesne A; Judson I; Crowther D; Rodenhuis S; Keizer HJ; Van Hoesel Q; Blay JY; Frisch J; Van Glabbeke M; Hermans C; Van Oosterom A; Tursz T; Verweij J
J Clin Oncol; 2000 Jul; 18(14):2676-84. PubMed ID: 10894866
[TBL] [Abstract][Full Text] [Related]
4. [Clinical study of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced leukopenia].
Shi YK; Sun Y; Su M
Zhonghua Zhong Liu Za Zhi; 1994 Sep; 16(5):356-9. PubMed ID: 7895587
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R
J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic effects and pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in childhood cancer patients receiving myelosuppressive chemotherapy.
Furman WL; Fairclough DL; Huhn RD; Pratt CB; Stute N; Petros WP; Evans WE; Bowman LC; Douglass EC; Santana VM
J Clin Oncol; 1991 Jun; 9(6):1022-8. PubMed ID: 2033415
[TBL] [Abstract][Full Text] [Related]
7. Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide, and cisplatin.
Brugger W; Frisch J; Schulz G; Pressler K; Mertelsmann R; Kanz L
J Clin Oncol; 1992 Sep; 10(9):1452-9. PubMed ID: 1517788
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human granulocyte-macrophage colony-stimulating factor after combined chemotherapy in high-grade non-Hodgkin's lymphoma--a randomised pilot study.
Bergmann L; Karakas T; Knuth A; Lautenschläger G; Mitrou PS; Hoelzer D
Eur J Cancer; 1995 Dec; 31A(13-14):2164-8. PubMed ID: 8652236
[TBL] [Abstract][Full Text] [Related]
9. Failure of granulocyte-macrophage colony-stimulating factor to reduce febrile neutropenia in children with recurrent solid tumors treated with ifosfamide, carboplatin, and etoposide chemotherapy.
Marina NM; Shema SJ; Bowman LC; Rodman J; Douglass EC; Furman WL; Pappo A; Santana VM; Hudson M; Meyer WH
Med Pediatr Oncol; 1994; 23(4):328-34. PubMed ID: 8058003
[TBL] [Abstract][Full Text] [Related]
10. [Effect of recombinant human granulocyte colony-stimulating factor (rG-CSF) on chemotherapy-induced neutropenia in patients with lung cancer].
Ohnoshi T; Ueoka H; Kodani T; Kamei H; Kimura I
Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 2):911-8. PubMed ID: 1693062
[TBL] [Abstract][Full Text] [Related]
11. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer.
Woll PJ; Hodgetts J; Lomax L; Bildet F; Cour-Chabernaud V; Thatcher N
J Clin Oncol; 1995 Mar; 13(3):652-9. PubMed ID: 7533825
[TBL] [Abstract][Full Text] [Related]
12. Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial.
Logothetis CJ; Finn LD; Smith T; Kilbourn RG; Ellerhorst JA; Zukiwski AA; Sella A; Tu SM; Amato RJ
J Clin Oncol; 1995 Sep; 13(9):2272-7. PubMed ID: 7666085
[TBL] [Abstract][Full Text] [Related]
13. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.
Bunn PA; Crowley J; Kelly K; Hazuka MB; Beasley K; Upchurch C; Livingston R; Weiss GR; Hicks WJ; Gandara DR
J Clin Oncol; 1995 Jul; 13(7):1632-41. PubMed ID: 7602352
[TBL] [Abstract][Full Text] [Related]
14. Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with Hodgkin's disease: a phase I/II study.
Hovgaard DJ; Nissen NI
J Clin Oncol; 1992 Mar; 10(3):390-7. PubMed ID: 1740678
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cells for autografting in patients not eligible for bone marrow harvest.
Haas R; Hohaus S; Egerer G; Ehrhardt R; Witt B; Hunstein W
Bone Marrow Transplant; 1992 Jun; 9(6):459-65. PubMed ID: 1352717
[TBL] [Abstract][Full Text] [Related]
16. Sequential intermediate high-dose therapy with etoposide, ifosfamide and cisplatin for patients with germ cell tumors.
Mardiak J; Fuchsberger P; Lakota J; Sálek T; Sycová-Milá Z; Drahokoupilová M; Baláz M; Koza I
Neoplasma; 2000; 47(4):239-43. PubMed ID: 11043829
[TBL] [Abstract][Full Text] [Related]
17. Ifosfamide-based chemotherapy for patients with resistant germ cell tumors: the Memorial Sloan-Kettering Cancer Center experience.
Motzer RJ; Bajorin DF; Vlamis V; Weisen S; Bosl GJ
Semin Oncol; 1992 Dec; 19(6 Suppl 12):8-11. PubMed ID: 1336624
[TBL] [Abstract][Full Text] [Related]
18. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom.
Fosså SD; Kaye SB; Mead GM; Cullen M; de Wit R; Bodrogi I; van Groeningen CJ; De Mulder PH; Stenning S; Lallemand E; De Prijck L; Collette L
J Clin Oncol; 1998 Feb; 16(2):716-24. PubMed ID: 9469362
[TBL] [Abstract][Full Text] [Related]
19. Sequential studies on the role of mitoxantrone, high-dose cytarabine, and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of refractory non-Hodgkin's lymphoma.
Ho AD; Del Valle F; Haas R; Engelhard M; Hiddemann W; Rückle H; Schlimok G; Thiel E; Andreesen R; Fiedler W
Semin Oncol; 1990 Dec; 17(6 Suppl 10):14-8; discussion 18-9. PubMed ID: 2259918
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic granulocyte colony-stimulating factor allows escalation of chemotherapeutic dose intensity in advanced epithelial ovarian cancer.
Fanning J; Hilgers RD
Gynecol Oncol; 1996 Dec; 63(3):323-7. PubMed ID: 8946866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]